New hope for Alzheimer's psychosis: Long-Term drug trial underway
NCT ID NCT07459660
First seen Jun 25, 2026 · Last updated Aug 07, 2026 · Updated 4 times
Summary
This study is testing the long-term safety of a drug called ML007C-MA for people with Alzheimer's disease who also have hallucinations and delusions. About 210 adults who completed a previous study will take the drug twice daily for up to 52 weeks. The goal is to see if the drug remains safe and tolerable over time.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- ML007C-MA (a combination drug taken twice daily)
- What this could lead to
- If it works, this could provide a safe, long-term option to ease hallucinations and delusions in people with Alzheimer's disease.
- What could go wrong
- This is an early-phase, open-label study with no placebo group, so results may not confirm effectiveness. Side effects or lack of benefit could still occur.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PSYCHOSIS ASSOCIATED WITH ALZHEIMER'S DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Clinical Site
Anaheim, California, 92805, United States
-
Clinical Site
Doral, Florida, 33122, United States
-
Clinical Site
Miami, Florida, 33155, United States
-
Clinical Site
Miami, Florida, 33173, United States
-
Clinical Site
Miami Gardens, Florida, 33014, United States
-
Clinical Site
Orlando, Florida, 32807, United States
-
Clinical Site
Pernik, Pernik, 2304, Bulgaria
-
Clinical Site
Toulouse, 31059, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.